In CML Patients With New Diagnoses, STAMP Inhibitor Outperforms Imatinib and Second-Gen TKIs.

Published Date: 03 Jun 2024

According to experts, the benefit-risk profile may alter the way CML is treated.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Primary Sjögren's syndrome patients' B-Cell Stimulating Factors are associated with the growth of lymphomas.

2.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

3.

An inhibitor of JAK1 exhibits "remarkable" activity in T-cell lymphoma.

4.

Analysis of 2021 data shows new cancer diagnoses did not rebound as expected following pandemic

5.

New imaging guidelines for head and neck cancers, a step toward practice change


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot